Journal article

HPV-FASTER: broadening the scope for prevention of HPV-related cancer

F Xavier Bosch, Claudia Robles, Mireia Diaz, Marc Arbyn, Iacopo Baussano, Christine Clavel, Guglielmo Ronco, Joakim Dillner, Matti Lehtinen, Karl-Ulrich Petry, Mario Poljak, Susanne K Kjaer, Chris JLM Meijer, Suzanne M Garland, Jorge Salmeron, Xavier Castellsague, Laia Bruni, Silvia de Sanjose, Jack Cuzick

NATURE REVIEWS CLINICAL ONCOLOGY | NATURE PUBLISHING GROUP | Published : 2016

Abstract

Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer enormous potential for cancer prevention, notably prevention of cervical cancer. The effectiveness of these approaches is, however, suboptimal owing to limited implementation of screening programmes and restricted indications for HPV vaccination. Trials of HPV vaccination in women aged up to 55 years have shown almost 90% protection from cervical precancer caused by HPV16/18 among HPV16/18-DNA-negative women. We propose extending routine vaccination programmes to women of up to 30 years of age (and to the 45-50-year age groups in some settings), paired with at least one HPV-screening test at age 30 years or o..

View full abstract

Grants

Awarded by European Union Seventh Framework Programme


Awarded by Spanish Ministry of Economy and Competitiveness via the Instituto de Salud Carlos III


Awarded by Government of Catalonia via the Agencia de Gestio d'Ajuts Universitaris i de Recerca (Agency for Management of University and Research Grant)


Awarded by German Guideline Program in Oncology (German Cancer Aid project)


Awarded by Bill and Melinda Gates Foundation


Awarded by Cancer Research UK


Funding Acknowledgements

The authors are grateful for the work of all the collaborators and personnel involved in the HPV European Consortium. The work of the authors was partially supported by the European Union Seventh Framework Programme (grant agreement #603019; CoheaHr) to all authors except S. M. G. and J. S.; the Spanish Ministry of Economy and Competitiveness via the Instituto de Salud Carlos III (RD12/0036/0056 and CIBERESP) to F. X. B., C. R., M. D., X. C., L. B. and S. d. S.; the Government of Catalonia via the Agencia de Gestio d'Ajuts Universitaris i de Recerca (Agency for Management of University and Research Grant 2014SGR1077 and 2014SGR2016 to F. X. B., C. R., M. D., X. C., L. B. and S. d. S.); the Lilly Foundation (Premio de Investigacion Biomedica Preclinica 2012 to F. X. B.); the National Institute of Public Health and the Environment (Bilthoven, Netherlands) to M. A.; the German Guideline Program in Oncology (German Cancer Aid project # 110163 to M. A.); the Belgian Health Care Knowledge Centre (Brussels, Belgium) to M. A.; the Bill and Melinda Gates Foundation (OPP1053353 to I. B.); the Institut National du Cancer to C. C.; Zorgonderzoek Nederland-Medische Wetenschappen (ZON-MW) and the Dutch Cancer Society to C. J. L. M. M.; and Cancer Research UK (C569/A16891 to J. C.).